Michigan's Bio-Industry a $55.72 Billion Economic Driver

January 3, 2025

Michigan’s Life Sciences Surge: $55.72B Impact, 8% Job Growth, and National Leadership in Key Sectors

Ann Arbor, Mich. – Newly released assessment shows Michigan’s life sciences industry grew by impressive numbers and retains a lead ranking nationally in several key cluster areas.

 

Michigan, a state with a sizeable biosciences cluster with a rich legacy of life science innovation now boasts of 3,319 establishments and 47,815 individuals directly employed across the state. Coupled with an average wage of $110,204, the cluster’s total economic impact grew by 24% to $55.72 billion. What an astounding achievement!

 

The data comes from Biotechnology Innovation Organization (BIO) and TEConomy, in partnership with the Council of State Bioscience Associations (CSBA, of which MichBio is an affiliate) that issued its biennial report, The U.S. Bioscience Economy: Driving Economic Growth and Opportunity in States and Regions in early December 2024. The analysis provides comprehensive national and state-level data on the U.S. bioscience industry’s economic performance, its impacts, and its geographic footprint.

 

Some key highlights of Michigan’s life science cluster growth found in the state-specific profile:

  • 8% job growth since 2022, and 12.2% increase from 2019.
  • 8% growth in establishments since 2022 (and 61.9% change from 2019).
  • 8% increase in average annual wage compared to 2022 (a 14.3% change from 2019); 66% higher than the private sector average in Michigan.
  • 10th largest nationally in bioscience research expenditures
  • $991.1 million in FY2023 NIH funding; a 20.2% increase since 2019
  • 5th and 9th largest medical device sector nationally based on # establishments and employment, respectively (a 36.8% and 9.6% increase correspondingly over 2022)
  • 6th and 10th largest biopharmaceutical sector nationally based on # establishments and employment, respectively (a 65.8% and 14.7% increase correspondingly over 2022)
  • 9th largest nationally in # of establishment comprising the agri-biosciences (i.e., bioeconomy) sector
  • #1 biopharmaceutical and medical device Medium Metropolitan Statistical Area (MSA) – Kalamazoo


“The new data reflects a robust expansion of Michigan’s biosciences cluster likely due to both organic growth at established companies, along with a surge in new company formation and technology commercialization,” said Stephen Rapundalo, PhD, President and CEO, MichBio. “It all starts with our world-class research universities where new discoveries are the substrate for new innovation and product development across the medtech, pharma, healthtech and agri-biotech sectors.”

 

Dr. Rapundalo further noted that “while the overall news bodes well for the statewide life sciences industry, it’s imperative that Michigan continue to develop resources and programs that can fuel the cluster’s future growth while providing good paying jobs for Michigan’s STEM talent. There is significant interest nationally in building regional life science hubs and Michigan must do everything possible to remain competitive.”

 

————————

 

MichBio is the only statewide trade association committed to driving growth in Michigan’s biosciences industry and its many sectors, including agricultural/industrial biotech, medical devices, pharmaceuticals, academic/clinical research, testing and research services, healthcare and information technologies, and bioscience products distribution. MichBio members include bioscience companies, research institutions, manufacturing suppliers and service providers, and related organizations. MichBio is here to support Michigan’s bioscience researchers, innovators, and producers, as well as those in the broader ecosystem that serve to sustain them. Through advocacy, programming, connecting, and business resources we help the state’s biosciences community thrive. For more information, visit www.michbio.org or follow us on LinkedIn and X.

RECENT ARTICLES

Upcoming Webinar - Prenuptial Patenting

April 24, 2025
Prenuptial Patenting: Responsible Engagement with Engineering Firms

Member Feature: PharmOptima

April 24, 2025
PharmOptima, a Poratge, Michigan-based preclinical contract research organization (CRO) is advancing drug discovery through its comprehensive suite of services. Specializing in in-vivo ADME/PK, ocular research, as well as regulated large and small molecule bioanalytical and ligand binding services, PharmOptima supports clients in optimizing drug development programs efficiently and effectively. With a staff averaging 11 years of industry experience and multiple individuals with advanced degrees, PharmOptima also boasts one of the most capable and engaging teams in the industry. The company collaborates with board-certified veterinary ophthalmologist Dr. Ryan Boyd, further enhancing its ocular research capabilities. PharmOptima's team of experts is dedicated to providing high-quality services to the pharmaceutical biotechnology industries. Looking ahead, PharmOptima scientists will be presenting posters at the 2025 The Association for Research in Vision and Ophthalmology (ARVO) conference, showcasing their latest research and innovations in ocular drug development. For more information visit www.pharmoptima.com .

Prohibition of Pathogen Gain of Function Legislation Re-Introduced

April 24, 2025
Two bills, HB 4332 and HB 4333 were recently re-introduced that would prohibit pathogen gain-of-function (GoF) research. Given that the House is now Republican-led raises concerns for MichBio and others that the legislation might gain traction due to misinformation over biosafety and pandemic origins. MichBio opposes such broad legislative bans as they risk undermining critical scientific progress, public health preparedness, and economic innovation. GoF research has been instrumental in developing life-saving therapies and vaccines. For instance, viral vector-based gene therapies, such as Sarepta's Elevidys for Duchenne muscular dystrophy, and oncolytic virotherapies like Amgen's Imlygic for melanoma, rely on genetically modified viruses to deliver therapeutic genes or selectively destroy cancer cells. These advancements stem from GoF methodologies that enhance viral capabilities for therapeutic purposes. Moreover, GoF research has played a pivotal role in vaccine development. Examples like the AstraZeneca and Janssen COVID-19 vaccines and Merck's ERVEBO vaccine against Ebola employs a genetically modified virus to confer protection, underscore the public health benefits derived from GoF studies. ​ Contrary to concerns that GoF research operates without sufficient oversight, multiple layers of regulation are in place. Since 2017, the U.S. Department of Health and Human Services has implemented a framework to evaluate and guide funding decisions for GoF research, particularly those involving potential pandemic pathogens. This framework includes stringent safety protocols, risk assessments, and ethical reviews. ​ MichBio is most concerned that any legislative bans that broadly define and prohibit GoF research risk stifling innovation across various scientific fields. Such bans could inadvertently encompass research in virology, microbiology, molecular biology, and synthetic biology—disciplines vital for developing new therapies, sustainable agricultural practices, and environmental remediation technologies. ​ In turn, state-level bans on GoF research could have detrimental effects on local economies and academic institutions. Such a ban could impede research critical to understanding and combating diseases, leading to a loss of federal and philanthropic funding. This could hamper the growth of the Michigan's biotech and biomedical sectors. ​  MichBio advocates for a balanced approach that reinforces existing oversight mechanisms and fosters transparent, responsible research practices essential to safeguard both public health and scientific progress.